KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Accumulated Expenses (2018 - 2025)

Twist Bioscience (TWST) has disclosed Accumulated Expenses for 6 consecutive years, with $24.3 million as the latest value for Q1 2023.

  • On a quarterly basis, Accumulated Expenses changed N/A to $24.3 million in Q1 2023 year-over-year; TTM through Mar 2023 was $24.3 million, a N/A change, with the full-year FY2022 number at $27.0 million, up 21.03% from a year prior.
  • Accumulated Expenses was $24.3 million for Q1 2023 at Twist Bioscience, down from $27.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $27.0 million in Q3 2022 to a low of $2.4 million in Q1 2019.
  • A 5-year average of $10.6 million and a median of $6.0 million in 2019 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 175.39% in 2019, then decreased 26.45% in 2020.
  • Twist Bioscience's Accumulated Expenses stood at $4.7 million in 2019, then skyrocketed by 147.0% to $11.6 million in 2020, then surged by 61.83% to $18.7 million in 2021, then soared by 44.24% to $27.0 million in 2022, then decreased by 10.15% to $24.3 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Accumulated Expenses are $24.3 million (Q1 2023), $27.0 million (Q3 2022), and $9.5 million (Q2 2022).